Food and Drug Administration The U.S. Food and Drug Administration clears the Fujirebio Lumipulse for distribution, the first blood test that can be used to diagnose Alzheimer's disease in people 55 years or older with memory problems by detecting amyloid plaques. Alzheimer's can currently only be diagnosed using a PET scan. Sources: FDA NPR